AAGH on OTC
America Great Health
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Selecta Biosciences (United States), Can Fite Biopharma or MEDICINOVA INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue7¢$52.6K
- Selling, general and admin93¢$722.1K
Out of $391.7K in revenue.3 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-06-30 | 2024-06-30 |
|---|---|---|
| Sales | $391.7K | $294.7K |
| Cost of goods sold | $52.6K | $124.9K |
| Gross profit | $339.1K | $169.8K |
| Selling expense | $50.9K | $95.8K |
| General and administrative expense | $671.2K | $856.6K |
| Selling, general and administrative expenses | $722.1K | $952.5K |
| Loss from operations | -$382.9K | -$782.7K |
| Interest income | $46 | $61 |
| Interest expense | -$338.4K | -$443.7K |
| Other income (expenses) | -$338.3K | -$443.7K |
| Loss before income taxes | -$721.2K | -$1.2M |
| NET LOSS | -$721.2K | -$1.2M |
| BASIC LOSS PER SHARE (in Dollars per share) | $0.00 | $0.00 |
| DILUTED LOSS PER SHARE (in Dollars per share) | $0.00 | $0.00 |
| BASIC (in Shares) | 21.1B shares | 21.1B shares |
| DILUTED (in Shares) | 21.1B shares | 21.1B shares |
| Non-controlling interest share of loss | -$2.1K | -$5.8K |
| Net loss attributed to the owners of the Company | -$719.1K | -$1.2M |
| Foreign currency transaction | -$443 | $983 |
| Comprehensive loss | -$719.6K | -$1.2M |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|
| Cash | $44.1K | $54.9K | |
| Account receivable, net | $0 | $55.1K | |
| Inventory | $164.7K | $83.1K | |
| Prepaid and other assets | $28.0K | $32.3K | |
| TOTAL CURRENT ASSETS | $236.7K | $225.5K | |
| Right-of-use asset, net | $25.2K | $43.3K | |
| Other assets | $11.8K | $11.8K | |
| Property and equipment, net | $28.1K | $42.9K | |
| TOTAL ASSETS | $301.8K | $323.5K | |
| Accounts payable | $1.5M | $1.4M | |
| Tax payable | $3.8K | $1.7K | |
| Short term loan | $595.1K | $607.0K | |
| Other payable | $18.9K | $118.4K | |
| Wage and wage tax payable | $359.0K | $239.1K | |
| Due to related party | $1.3M | $1.1M | |
| Advances from customers | $78.0K | $59.6K | |
| Lease liability current | $25.2K | $21.7K | |
| TOTAL CURRENT LIABILITIES | $3.8M | $3.6M | |
| Lease liability non-current | $0 | $21.6K | |
| Long term loan | $2.2M | $1.8M | |
| Total Non-Current liabilities | $2.2M | $1.9M | |
| TOTAL LIABILITIES | $6.0M | $5.4M | |
| Commitments and Contingencies | $0 | $0 | |
| Redeemable, convertible preferred stock, 10,000,000 shares authorized: Series A voting preferred stock, zero shares issued and outstanding | $0 | $0 | |
| Common stock, no par value, unlimited shares authorized; 21,152,711,608 and 21,136,888,326 shares issued and Outstanding | $0 | $0 | |
| Additional paid-in capital | $5.1M | $5.0M | |
| Treasury stock: 52,150,000 shares as of June 30, 2025 and 52,100,000 as of June 30, 2024 | $0 | $0 | |
| Accumulated other comprehensive income | -$1.0K | -$1.5K | |
| Accumulated deficit | -$10.8M | -$10.1M | |
| Total deficit attributable to owners of the Company | -$5.7M | -$5.0M | |
| Non-controlling interest | -$82.6K | -$80.5K | |
| TOTAL SHAREHOLDERS DEFICIT | -$5.7M | -$5.1M | -$4.2M |
| TOTAL LIABILITIES AND SHAREHOLDERS DEFICIT | $301.8K | $323.5K | |
| Series A voting preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Series A voting preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Redeemable, convertible preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Common stock, shares issued (in Shares) | 21.2B shares | 21.1B shares | |
| Common stock, shares outstanding (in Shares) | 21.2B shares | 21.1B shares | |
| Treasury stock, shares (in Shares) | 52.1M shares | 52.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-06-30 | 2024-06-30 |
|---|---|---|
| Net loss | -$721.2K | -$1.2M |
| Depreciation | $14.8K | $14.8K |
| Original issue discount | $0 | $48.0K |
| Stock compensation | $0 | $123.6K |
| (Reversal)/Increase of inventory provision | -$400 | $9.4K |
| Payment of lease and rent | -$82.6K | -$80.4K |
| Right of use asset net | $18.1K | -$1.3K |
| Lease liabilities net | $5.2K | $47.2K |
| Account receivable net | $55.1K | -$55.1K |
| Prepaid expenses and other assets | $4.3K | -$15.3K |
| Inventory | -$81.1K | $15.8K |
| Accounts payable and accrued expense | $112.7K | $19.9K |
| Customer advances | $18.4K | -$8.7K |
| Accrued interest for short term loan | $60.1K | $117.8K |
| Accrued interest for long term loan | $241.1K | $261.8K |
| Tax payable | $2.2K | $800 |
| Other payable | -$99.5K | $90.8K |
| Wage and wage tax payable | $119.9K | $21.8K |
| Net cash used in operating activities from continuing operations | -$332.9K | -$615.6K |
| Net cash used in operating activities | -$332.9K | -$615.6K |
| Net cash used in investing activities | $0 | $0 |
| Proceeds from issuance of common stock | $102.1K | $115.0K |
| Proceeds of short term loan | $0 | $37.5K |
| Repayment of short term loan | -$10.8K | -$201.9K |
| Interest payment to short term loan | -$61.3K | -$73.4K |
| Proceeds of long term loan | $150.0K | $60.0K |
| Repayment of long term loan | $0 | -$10.0K |
| Interest payment to long term loan | $0 | -$3.0K |
| Advances from related party | $635.0K | $969.9K |
| Repayment to related party | -$493.6K | -$276.6K |
| Net cash provided by financing activities | $321.5K | $617.4K |
| Net (decrease) increase in cash | -$11.3K | $1.8K |
| Effect of foreign currency translation | $443 | -$983 |
| Interest paid | $61.3K | $76.4K |
| Taxes paid | $800 | $800 |
Former names
Recent filings
- Sep 25, 2026NT 10-K
- Aug 24, 20268-K
- Aug 6, 202610-Q
- Jun 22, 202610-Q
- Jun 4, 202610-Q
- Apr 10, 202610-K
- Sep 29, 2025NT 10-K
- Sep 15, 20258-K
- May 15, 202510-Q
- Apr 14, 202510-Q
- Mar 27, 202510-Q
- Feb 25, 202510-K
- Nov 15, 2024NT 10-Q
- Oct 25, 20248-K
- Oct 18, 20248-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8